Publications

Export 21446 results:
Sort by: [ Author  (Asc)] Title Type Year
[A] B C D E F G H I J K L M N O P Q R S T U V W X Y Z   [Show ALL]
A
Azim, H. A., L. Kassem, I. Treilleux, Q. Wang, M. A. E. Enein, S. E. Anis, and T. Bachelot, Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer, , vol. 9, issue 2: Elsevier, pp. 114 - 123, 2016. Abstract
n/a
Azim, H. A., O. Abdel-Rahman, and R. Abdel-Malek, Bilateral Phyllodes Tumor of the Breast; a Case Report of Benign Tumor on One Side and Malignant Tumor on the Contralateral Side, , vol. 13, issue 2: Cairo University, Faculty of Medicine, Kasr Al-Ainy Center of Clinical …, pp. 56 - 58, 2017. Abstract
n/a
Azim, H. A., L. Kassem, shady elia anis, I. Treilleux, Q. Wang, M. A. E. Enein, and T. Bachelot, "Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer.", Translational Oncology , vol. 9, issue 2, pp. 114-123, 2016. paper_1.pdf
Azim, H. A., and H. A. Azim Jr, Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions, , vol. 8, issue 2: Future Medicine, pp. 135 - 144, 2012. Abstract
n/a
Azim, H. A., N. S. Kamal, and R. A.Malek, "Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!", Journal of Thoracic Diseases, vol. 5, issue suppl 1, pp. 27-35, 2013.
Azim, H. A., L. Kassem, K. S. Shohdy, B. Eshaak, shady elia anis, and N. S. Kamal, Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin, , vol. 22, issue 1, pp. 141 - 148, 2019. Abstract
n/a
tarek Azim, "Production of charged Higgs-Boson and Z-Boson", Arab journal of nuclear sciences and applications, vol. 35, issue 3, pp. 165, 2001.
tarek Azim, "Higgs-Boson production together with neutrino pair at e + e- colliders ", Heavy ion physics , issue 5, pp. 151, 1997.
Azim, H. A., L. Kassem, K. S. Shohdy, B. Eshaak, shady elia anis, and N. S. Kamal, "Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin", Journal of Breast Cancer, vol. 22, issue 1, pp. e2 - e2, 2019///. Abstract

The assessment of motor conduction along the pudendal nerve is an accurate objective measure of pudendal nerve function. Measurement of its latency (that is the time interval between electrical stimulation of the nerve and induced contraction of the external anal sphincter) has been demonstrated to be abnormally long following vaginal delivery, particularly if the delivery was associated with a heavy fetus or a prolonged second stage of labor. The significance of pudendal neuropathy and its relationship to abnormal degrees of descent of the pelvic floor have also been examined in this review.

Azim, S. A. A., R. M. Hussein, A. A. Badr, and M. R. Rizk, "Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells Against Isoniazid and RifampicinInduced Hepatorenal Toxicity in Rats ", Life Science Journal , vol. 11, issue 12, pp. 1036-1046, 2014.
Azim, H. A., S. Dawood, N. El‐Saghir, L. Kassem, and H. A. Azim, Understanding the benefits and challenges of first‐line cyclin‐dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women, : John Wiley & Sons, Ltd (10.1111), Submitted. Abstract
n/a
Azim, H. A., N. S. Kamal, and H. A. Azim Jr, Bone metastasis in breast cancer: the story of RANK-ligand, , vol. 24, issue 3: Elsevier, pp. 107 - 114, 2012. Abstract
n/a
Azim, H. A., R. Abdel-Malek, and L. Kassem, Predicting brain metastasis in breast cancer patients: stage versus biology, , vol. 18, issue 2: Elsevier, pp. e187 - e195, 2018. Abstract
n/a
Azim, H. A., Y. S. Abdal-Kader, M. M. Mousa, R. Abdel-Malek, M. K. Abdalmassih, and N. O. H. A. Y. E. H. I. A. IBRAHIM, "Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients", Asian Pacific Journal of Cancer Prevention, vol. 16, issue 1, pp. 65-69, 2015. 65-69_7.26_hamdy_a_azim.pdf
Azim, E.: A. A., H. Abdelhalim, and E. Helmy, Comparison Between Applying Acidification Method for Alum recovery of Different Clarifier Type, , 2013. Abstract

Abstract
Alum sludge produced from water treatment plants contains aluminum hydroxide mixed with suspended solids in raw water. The aim of this research is to study aluminium sulphate (alum) recovery from alum sludge in aqueous solution by acidification process using sulphuric acid, and compare the results of applying the acidification method to the alum sludge produced from different clarifier types.
The results of the experimental works showed that the recovered alum volume produced from pulsator system after acidification process is the best value with percent recovery 98%, then the high rate system with percent recovery 96.4%, and the classical system with percent recovery 94%. All these percentage achieved at the liquid sludge.
The concentration of recovered alum occurred by acidifying the sludge produced from classical clarifier, the high rate type and the pulsator type are 20.2%, 18.5% and 13.90% respectively. The recovered alum can reduce turbidity with percentage 84.2% in the classical clarifier type, 79.52% in the high rate clarifier type and 76.47 in the pulsator clarifier type. A mixture of recovered alum and fresh alum can also be used to improve the coagulation process.

Azim, H. A., M. K. A. 12 Yasser S Abdal-Kader Mohamed Mahmoud Mousa1, Raafat Abdel Malek1, M. M. Mousa, R. A. Malek, M. K. Abdalmassih, and N. Y. Ibrahim, "Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients", Asian Pacific Journal Cancer Prevention, vol. 16, issue 1, pp. 65-69, 2015. 65-69_7.26_hamdy_a_azim-2.pdf
Azim, A. A. Y., A. S. Hanafy, and E. E. Khalil, "Subcooled Flow Boiling of Water Enhancement by Using Internal Surface Coating", International Journal of Thermal & Environmental Engineering, Jordan, 10 Dec., 2011.
Azim, S. A. A., H. A. Darwish, M. Z. Rizk, S. A. Ali, and M. O. Kadry, "Amelioration of titanium dioxide nanoparticles-induced liver injuryin mice: Possible role of some antioxidants", Experimental and Toxicologic Pathology, vol. 67 , pp. 305–314, 2015.
tarek Azim, "Production cross-section for the charged Goldston G+,G- and Z-Boson via e+ e- ---> Z G+ G-", Arab journal of nuclear sciences and applications, 2004.
Azim, H. A., E. Isaak, E. Elsissy, R. Khalifa, A. Mohamed, and N. Kassem, CK19 as a predictor of micrometastasis in breast cancer patients, , 2009.
tarek Azim, "Production of supersymmetric particles and W -gauge boson at e + e- supercollider ", International conference on modem development in elementary particles physics, pp. 24, 1999.
Azim, H. A., R. Abdel-Malek, and L. Kassem, "Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.", Clinical breast cancer, 2017 Aug 18. Abstract

BACKGROUND: Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer.

PATIENTS AND METHODS: We reviewed the clinical records of 2193 consecutive breast cancer patients who presented between January 1999 and December 2010. We explored the incidence of BM in relation to standard clinicopathological factors, and determined the cumulative risk of BM according to the disease stage and phenotype.

RESULTS: Of the 2193 included women, 160 (7.3%) developed BM at a median follow-up of 5.8 years. Age younger than 60 years (P = .015), larger tumors (P = .004), lymph node (LN) positivity (P < .001), high tumor grade (P = .012), and HER2 positivity (P < .001) were associated with higher incidence of BM in the whole population. In patients who presented with locoregional disease, 3 factors independently predicted BM: large tumors (hazard ratio [HR], 3.60; 95% confidence interval [CI], 1.54-8.38; P = .003), axillary LN metastasis (HR, 4.03; 95% CI, 1.91-8.52; P < .001), and HER2 positivity (HR, 1.89; 95% CI, 1.0-3.41; P = .049). A Brain Relapse Index was formulated using those 3 factors, with 5-year cumulative incidence of BM of 19.2% in those having the 2 or 3 risk factors versus 2.5% in those with no or 1 risk factor (P < .001). In metastatic patients, 3 factors were associated with higher risk of BM: HER2 positivity (P = .007), shorter relapse-free interval (P < .001), and lung metastasis (P < .001).

CONCLUSION: Disease stage and biological subtypes predict the risk for BM and subsequent treatment outcome.

Azim, H. A., K. S. Shohdy, D. F. Kaldas, L. Kassem, and H. A. Azim, "Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis", Current Problems in Cancer, vol. 44, issue 6, pp. 100592 - 100592, 2020/12//. Abstract
n/a
Azim, H. A., A. Omar, H. Atef, H. Zawahry, M. K. Shaker, A. H. K. Abdelmaksoud, M. EzzElarab, O. Abdel-Rahman, M. Ismail, L. Kassem, et al., "Sorafenib plus tegafur-uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study).", Journal of hepatocellular carcinoma, vol. 5, pp. 109 - 119, 2018///. AbstractWebsite

Background Phase II trials found that tegafur-uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. Our Phase II randomized trial aimed to evaluate efficacy and tolerability of sorafenib plus UFT vs sorafenib in advanced HCC. Methods Patients with advanced HCC, with no prior systemic therapy, were randomized to receive either UFT at 125 mg/m2 twice daily for 4 out of 5 weeks plus sorafenib at 400 mg twice daily (arm 1) or single agent sorafenib at 400 mg twice daily (arm 2). Primary end point was time to progression (TTP). Results Between March 2012 and March 2014, 76 eligible patients - out of 143 preplanned - were randomized. The study was terminated early because of futility. This is the final analysis of the study, after a median follow-up of 10.2 months and death of 86% of randomized patients (n=64). Median TTP was 7.5 months and 8.2 months in arms 1 and 2 respectively (HR: 1.07; 95% CI, 0.52-2.22; P=0.855), while the median overall survival was 8.2 months and 10.5 months respectively (HR: 1.58; 95% CI: 0.90-2.76, P=0.112). Nine patients (25%) in the combination arm discontinued treatment because of toxicity vs eight patients (21.1%) in the sorafenib monotherapy arm (P=0.899). Conclusion In patients with advanced HCC, adding UFT to sorafenib is feasible, but it did not improve efficacy outcome over sorafenib monotherapy.

Azim, H. A., R. A. Malek, and H. A. A. Jr, "Pathological features and prognosis of lobular carcinoma in Egyptian breast cancer patients", Women's Health, vol. 10, issue 5, pp. 511-518, 2014. 5.ilc_2014.pdf
Tourism